Case Studies

Patented Medicine Prices Review Board (PMPRB)

A manufacturer established a premium price for an innovative new product. PMPRB alleged excessive pricing and excess revenues of more than $20M based on a therapeutic class comparison (TCC). PDCI developed a strategy, organized meetings, liaised with PMPRB staff, and prepared submissions challenging the comparators included in the TCC and provided a compelling rationale justifying why the price had never been excessive. The PMPRB ultimately agreed and the manufacturer was able to maintain its price and no repayment was required.

The PMPRB ultimately agreed and the manufacturer was able to maintain its price and no repayment was required.

Pharmaceutical Market Potential

PDCI researched the international pricing and reimbursement environment for HPV vaccines for a client investigating investment opportunities in the HPV vaccine market. We gathered information on pricing and reimbursement policies impacting HPV vaccines in United States and major European markets, and prepared a report including:

  • summaries of the vaccine funding/reimbursement systems in each market
  • how HPV vaccines are perceived and likely to be funded/reimbursed
  • market access opportunities / challenges for each market
  • an estimate of the proportion (expressed as a percentage) of the patient population that might be eligible for reimbursement

Pricing Practices in Emerging Pharmaceutical Markets

PDCI conducted a market research study on the pricing practices of global pharmaceutical companies in low and middle income markets. Our research included providing an overview of the pricing and reimbursement environments and investigating pricing strategies in a wide range of countries including the rapidly emerging “BRIC” countries – Brazil, Russia, India, and China.

…investigating pricing strategies in a wide range of countries including the rapidly emerging “BRIC” countries…

Summary of Discussion at a Pricing and Reimbursement Advisory Board Meeting

PDCI prepared reports summarizing pre-meeting responses and advisory board meeting discussions related to pricing and reimbursement in two disease areas: Acute Coronary Syndromes and Kidney Disease.